Skip to main content
SpringerLink
Log in

Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients

  • Educational Series
  • Advances in Clinical Management and Therapy of Cancer
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Treatment of anaemia is a very important aspect in the management of cancer patients. In order to carry out a consensus process about the use of erythropoietic stimulating agents (ESAs) in cancer patients, the Spanish Society of Medical Oncology (SEOM) elaborated a working group which coordinated a panel of medical oncology specialists. This working group has reviewed the main issues about the use of ESAs. In addition a consensus meeting was held in Madrid on 25 April 2007. The following conclusions were made: Since ESA treatment increases the haemoglobin (Hb) level and decreases the red blood cell (RBC) transfusion requirements, ESAs should be used within the approved indications in patients undergoing chemotherapy treatment, beginning at a Hb level below 11 g/dl and maintaining it around 12 g/dl, with iron supplements if necessary. Neither increasing the ESA dose in non-responders nor the use of ESAs in the treatment of chronic cancer-related anaemia is recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ludwig H, Van Belle S, Barrett-Lee P et al (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:2293–2306

    Article  PubMed  Google Scholar 

  2. Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616–1634

    Article  CAS  PubMed  Google Scholar 

  3. Crawford J, Cella D, Cleeland CS et al (2002). Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95:888–895

    Article  CAS  PubMed  Google Scholar 

  4. American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671–679

    Google Scholar 

  5. Gascón P (2005) Evaluating erythropoietic agents for the treatment of anaemia in the oncology setting. Eur J Cancer 41:2601–2612

    Article  PubMed  CAS  Google Scholar 

  6. Ludwig H, Fritz E, Kotzmann H et al (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693–1699

    CAS  PubMed  Google Scholar 

  7. Demetri GD, Kris M, Wade J et al (1998) Qualityof-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16:3412–3425

    CAS  PubMed  Google Scholar 

  8. Gabrilove JL, Cleeland CS, Livingston RB et al (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875–2882

    CAS  PubMed  Google Scholar 

  9. Shasha D, George MJ, Harrison LB (2003) Onceweekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 98:1072–1079

    Article  CAS  PubMed  Google Scholar 

  10. Quirt I, Robeson C, Lau CY et al (2001) Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 19:4126–4134

    CAS  PubMed  Google Scholar 

  11. Savonije JH, van Groeningen CJ, Wormhoudt LW, Giaccone G (2006) Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level. Oncologist 11:206–216

    Article  CAS  PubMed  Google Scholar 

  12. Bamias A, Aravantinos G, Kalofonos C et al (2003) Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology 64:102–110

    Article  CAS  PubMed  Google Scholar 

  13. Henry DH (2007) Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies. Drugs 67:175–194

    Article  CAS  PubMed  Google Scholar 

  14. Cascinu S, Fedeli A, Del Ferro E et al (1994) Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 12:1058–1062

    CAS  PubMed  Google Scholar 

  15. Henry DH, Brooks BJ Jr, Case DC Jr et al (1995) Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am 1:252–260

    CAS  PubMed  Google Scholar 

  16. Witzig TE, Silberstein PT, Loprinzi CL et al (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23:2606–2617

    Article  CAS  PubMed  Google Scholar 

  17. Chang J, Couture F, Young S et al (2005) Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 23:2597–2605

    Article  CAS  PubMed  Google Scholar 

  18. Scott SN, Boeve TJ, McCulloch TM et al (2002) The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study. Laryngoscope 112:1221–1229

    Article  CAS  PubMed  Google Scholar 

  19. J Littlewood TJ, Bajetta E, Nortier JW et al (2001) Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865–2874

    Google Scholar 

  20. Wilkinson PM, Antonopoulos M, Lahousen M et al (2006) Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial. Br J Cancer 94:947–954

    Article  CAS  PubMed  Google Scholar 

  21. Abels RI, Larholt KM, Krantz KD, Bryant EC (1996) Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. Oncologist 1:140–150

    CAS  PubMed  Google Scholar 

  22. Dammacco F, Castoldi G, Rödjer S (2001) Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113:172–179

    Article  CAS  PubMed  Google Scholar 

  23. Kurz Ch, Marth Ch, Windbichler G et al (1997) Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol Oncol 65:461–466

    Article  CAS  PubMed  Google Scholar 

  24. Kunikane H, Watanabe K, Fukuoka M et al (2001) Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with nonsmall cell lung cancer. Int J Clin Oncol 6:296–301

    Article  CAS  PubMed  Google Scholar 

  25. Pirker R, Lehnert M, Minar W (2007) Onceweekly epoetin beta (30,000 IU) in anemic patients with lung cancer receiving chemotherapy. Lung Cancer 55:89–94

    Article  PubMed  Google Scholar 

  26. Oberhoff C, Neri B, Amadori D et al (1998) Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 9:255–260

    Article  CAS  PubMed  Google Scholar 

  27. Boogaerts M, Oberhoff C, Ten Bokkel Huinink W et al (2006) Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a meta-analysis. Anticancer Res 26:479–484

    CAS  PubMed  Google Scholar 

  28. Vansteenkiste J, Pirker R, Massuti B et al (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211–1220

    CAS  PubMed  Google Scholar 

  29. Kotasek D, Steger G, Faught W et al (2003) Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 39:2026–2034

    Article  CAS  PubMed  Google Scholar 

  30. Hedenus M, Adriansson M, San Miguel J et al (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebocontrolled study. Br J Haematol 122:394–403

    Article  CAS  PubMed  Google Scholar 

  31. Bohlius J, Langensiepen S, Schwarzer G et al (2005) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97:489–498

    CAS  PubMed  Google Scholar 

  32. Bohlius J, Wilson J, Seidenfeld J et al (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708–714

    Article  CAS  PubMed  Google Scholar 

  33. Bokemeyer C, Aapro MS, Courdi A et al (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43:258–270

    Article  CAS  PubMed  Google Scholar 

  34. Östeborg A Boogaerts MA, Cimino R et al (1996) Recombinant human erythropoietin, epoetin beta in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma: a randomized multicenter study. Blood 87:2675–2682

    Google Scholar 

  35. Bogaaerts M, Coiffer B, Kainz C (2003) Impact of epoetin beta in quality of life in patients with malignant disease. Br J Cancer 88:988–995

    Article  CAS  Google Scholar 

  36. Seidenfeld J, Piper M, Flamm C et al (2001) Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93:1204–1214

    Article  CAS  PubMed  Google Scholar 

  37. Rizzo JD, Lichtin AE, Woolf SH et al (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083–4107

    Article  CAS  PubMed  Google Scholar 

  38. Iconomou G, Koutras A, Rigopoulos A et al (2003) Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial. J Pain Symptom Manage 25:512–518

    Article  CAS  PubMed  Google Scholar 

  39. Bohlius J, Langensiepen S Schwarzer G et al (2005) Erythropoietin for patients with malignant disease. Cochrane Libr 4

  40. Barrett-Lee P, Bokemeyer C, Gascón P et al (2005) Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist 10:743–757

    Article  CAS  PubMed  Google Scholar 

  41. Patton J, Reeves T, Wallace J (2004) Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist 9:451–454

    Article  CAS  PubMed  Google Scholar 

  42. Cella D, Hahn EA, Dineen K (2002) Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 11:207–221

    Article  PubMed  Google Scholar 

  43. Glaspy J, Bukowski R, Steinberg D et al (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15:1218–1234

    CAS  Google Scholar 

  44. Wu HS, McSweeney M (2004) Assessing fatigue in persons with cancer: an instrument development and testing study. Cancer 101:1685–1695

    Article  PubMed  Google Scholar 

  45. Hann DM, Jacobsen PB, Azzarello LM et al (1998) Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res 7:301–310

    Article  CAS  PubMed  Google Scholar 

  46. Gascón P, García-Mata J, Colomer R et al (2007) Final results of the validation of the PERFORM Questionnaire, a new questionnaire to assess the patient perception of cancer-related fatigue. Eur J Cancer [Suppl 4]:1159

    Google Scholar 

  47. Glaspy J, Henry D, Patel R et al (2005) Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 41:1140–1149

    Article  CAS  PubMed  Google Scholar 

  48. Hesketh PJ, Arena F, Patel D et al (2004) A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer 100:859–868

    Article  CAS  PubMed  Google Scholar 

  49. Case DC Jr, Bukowski RM, Carey RW et al (1993) Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85:801–806

    Article  PubMed  Google Scholar 

  50. Silvestris F, Romito A, Fanelli P et al (1995) Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol 70:313–318

    Article  CAS  PubMed  Google Scholar 

  51. Leyland-Jones B, Semiglazov V, Pawlicki M et al (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23: 5960–5972

    Article  CAS  PubMed  Google Scholar 

  52. (2007) Cancer and treatment-related anemia. NCCN Practice guidelines in Oncology, v2

  53. Glaspy J, Degos L, Dicato M, Demetri GD (2002) Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. Oncologist 7:126–135

    Article  CAS  PubMed  Google Scholar 

  54. ten Bokkel Huinink WW, de Swart CA, van Toorn DW et al (1998) Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 15:174–182

    Article  PubMed  Google Scholar 

  55. Cazzola M, Beguin Y, Kloczko J et al (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 122:386–393

    Article  CAS  PubMed  Google Scholar 

  56. Canon JL, Vansteenkiste J, Bodoky G et al (2006) Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 98:273–284

    Article  CAS  PubMed  Google Scholar 

  57. Ozguroglu M, Arun B, Demir G et al (2000) Serum erythropoietin level in anemic cancer patients. Med Oncol 17:29–34

    Article  CAS  PubMed  Google Scholar 

  58. Heatherington AC, Glaspy J, Kotasek D et al (2001) Changes endogenous erythropoietin and the pharmacokinetics of darbepoetin alfa in patients with non-myeloid malignancies receiving chemotherapy. Blood 98:298a–299a

    Google Scholar 

  59. Kaczorowska-Hac B, Balcerska A (2003) Endogenous erythropoietin levels in children with malignant disorders. Acta Haematologica Polonica 34:231–237

    Google Scholar 

  60. González-Barón M, Ordóñez A, Franquesa R et al (2002) Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy. Cancer 95:2408–2413

    Article  PubMed  CAS  Google Scholar 

  61. Fjornes T, Wiedemann GJ, Sack K, Jelkmann W (1998) Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy. Oncol Rep 5:81–86

    CAS  PubMed  Google Scholar 

  62. Auerbach M, Ballard H, Trout JR et al (2004) Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22:1301–1307

    Article  CAS  PubMed  Google Scholar 

  63. Henry DH, Dahl NV, Auerbach M et al (2007) Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12:231–242

    Article  CAS  PubMed  Google Scholar 

  64. Hedenus M, Birgegård G, Näsman P et al (2007) Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 21:627–632

    CAS  PubMed  Google Scholar 

  65. Lerchenmüller C, Husseini F, Gaede B et al (2006) Intravenous iron supplementation in patients with chemotherapy-induced anemia receiving darbepoetin alpha every 3 weeks: iron parameters in a randomized controlled trial. Blood 108:445

    Google Scholar 

  66. Engert A (2005) Recombinant human erythropoietin in oncology: current status and further developments. Ann Oncol 16:1584–1595

    Article  CAS  PubMed  Google Scholar 

  67. Pirker R (2007) Safety considerations for erythropoietin treatment in patients with cancer. Expert Opin Drug Saf 6:63–69

    Article  CAS  PubMed  Google Scholar 

  68. Henke M, Laszig R, Rübe C et al (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255–1260

    Article  CAS  PubMed  Google Scholar 

  69. Wright JR, Ung YC, Julian JA et al (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25:1027–1032

    Article  CAS  PubMed  Google Scholar 

  70. Coiffier B, Boogaerts M, Aapro M et al (2006) Effect of treatment with epoetin beta on thromboembolic events in anaemic patients with cancer: a meta-analysis. Supportive Cancer Ther 4:49–55

    Article  CAS  Google Scholar 

  71. Aapro M, Coiffier B, Dunst J et al (2006) Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: a meta-analysis. Br J Cancer 95:1467–1473

    Article  CAS  PubMed  Google Scholar 

  72. Frommhold H, Guttenberger R, Henke M (1998) The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience. Strahlenther Onkol 174[Suppl 4]:31–34

    Google Scholar 

  73. Obermair A, Petru E, Windbichler G et al (2000) Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer. Oncol Rep 7:639–644

    CAS  PubMed  Google Scholar 

  74. Littlewood T, Mandelli F (2002) The effects of anemia in hematologic malignancies: more than a symptom. Semin Oncol 29[3 Suppl 8]:40–44

    PubMed  Google Scholar 

  75. Bottini A, Berruti A, Brizzi MP et al (2003) Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer. Br J Cancer 89:977–982

    Article  CAS  PubMed  Google Scholar 

  76. Harrison LB, Chadha M, Hill RJ et al (2002) Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 7:492–508

    Article  PubMed  Google Scholar 

  77. Grogan M, Thomas GM, Melamed I et al (1999) The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86:1528–1536

    Article  CAS  PubMed  Google Scholar 

  78. Glaser CM, Millesi W, Kornek GV et al (2001) Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50:705–715

    CAS  PubMed  Google Scholar 

  79. Hedenus M, Hansen S, Taylor K et al (2002) Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 119:79–86

    Article  CAS  PubMed  Google Scholar 

  80. Alymara V, Kouskou F, Bouranta P et al (2004) Clinical evaluation of once weekly dosing of epoetin alpha in multiple myeloma patients: improvements in hemoglobin are similar to three-timesweekly dosing. Hematol J 5[S272]:abstr 815

    Google Scholar 

  81. Shasha D, Williams D (2004) Epoetin alfa 40,000 IU QW increases Hb and is safe in anemic patients not receiving chemotherapy or radiation therapy. Blood 104:A4223

    Google Scholar 

  82. Shasha D, Henry DH (2005) Hematopoietic response to extended dosing of epoetin alfa 60,000 IU every 2 weeks in anemic cancer patients not receiving therapy: final results. Blood 106:A3764

    Google Scholar 

  83. Baz R, Brand C, McGowan E et al (2005) High dose recombinant human erythropoietin use is associated with increased overall survival in patients with multiple myeloma. J Clin Oncol 23[Suppl 16]:6621

    Google Scholar 

  84. Bogdanos J, Karamanolakis D, Milathianakis K et al (2004) Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases. Anticancer Res 24:1957–1961

    CAS  PubMed  Google Scholar 

  85. Nowrusian MR Voigtman R (2003) Treatment with epoetin beta corrects anemia and decreases transfusion use in patients with solid tumours or haematological malignancies. Eur J Cancer [Suppl 1]:S176, abstr 581

  86. Charu V, Belani CP, Gill AN et al (2004) A controlled, randomized, open-label study to evaluate the effect of every two week darbepoetin alfa for anemia of cancer. J Clin Oncol 22[Suppl 14]:8084

    Google Scholar 

  87. Hedenus M, Vansteenkiste J, Kotasek D et al (2005) Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 23:6941–6948

    Article  CAS  PubMed  Google Scholar 

  88. Katodritou E, Speletas M, Zervas K et al (2005) Novel hematologic markers for predicting response to r-HuEPO in anemic patients with multiple myeloma and lymphoma. Hematol J 90[Suppl 2]:S187, abstr 0464

    Google Scholar 

  89. Bohlius J, Wilson J, Seidenfeld J et al (2006) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 3:CD003407

    CAS  PubMed  Google Scholar 

  90. Abels R (1993) Erythropoietin for anemia in cancer patients. Eur J Cancer 29A[Suppl 2]:2–8

    Article  Google Scholar 

  91. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes (1998) A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 103:1070–1074

    Article  Google Scholar 

  92. Smith RE, Tchekmedyian NS, Chan D et al (2003) A dose-and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 88:1851–1858

    Article  CAS  PubMed  Google Scholar 

  93. Thompson JA, Gilliland DG, Prchal JT et al (2000) Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group. Blood 95:1175–1179

    CAS  Google Scholar 

  94. Glaspy J, Smith R, Aapro M et al (2007) Results from a phase III, randomized, double-blind, placebo-controlled study of darbepoetin alfa for the treatment of anemia in patients not receiving chemotherapy or radiotherapy. Proc Am Assoc Cancer Res abstract LB-3

  95. Henke M, Guttenberger R, Barke A et al (1999) Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiother Oncol 50:185–190

    Article  CAS  PubMed  Google Scholar 

  96. Rades D, Schild SE, Yekebas EF et al (2005) Epoetin-alpha during radiotherapy for stage III esophageal carcinoma. Cancer 103:2274–2279

    Article  CAS  PubMed  Google Scholar 

  97. Antonadou D, Throuvalas N, Lavey R et al (2003) Final results of a randomized II study evaluating the role of erythropoietin during radiochemotherapy for pelvic tumors. Eur J Cancer Suppl 1:279

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Oncología Médica, 6.a planta, Hospital Arnau de Vilanova, C/San Clemente, 12, ES-46015, Valencia, Spain

    Vicente Alberola Candel

  2. Hospital General Universitario de Elche, Elche, Spain

    Alfredo Carrato Mena

  3. Hospital Clínico Universitario San Carlos, Madrid, Spain

    Eduardo Díaz-Rubio García & Miguel Martín Jiménez

  4. Hospital Clínic, Barcelona, Spain

    Pere Gascón Vilaplana

  5. Hospital Universitario La Paz, Madrid, Spain

    Manuel González Barón

  6. Hospital Virgen de la Victoria, Málaga, Spain

    Emilio Alba Conejo

  7. Hospital General Universitario de Guadalajara, Guadalajara, Spain

    Javier Cassinello Espinosa

  8. Centro Oncológico MD Anderson España, Madrid, Spain

    Ramon Colomer

  9. Hospital Clínico Universitario de Salamanca, Salamanca, Spain

    Juan Jesús Cruz Hernández & César Augusto Rodríguez Sánchez

  10. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    Agustí Barnadas i Molins

  11. Hospital General Universitario de Valencia, Valencia, Spain

    Carlos Camps Herrero & Joaquin Gavilá Gregori

  12. Hospital Virgen del Rocío, Sevilla, Spain

    Ana Ma. Casas Fernández de Tejerina

  13. Hospital Mateu Orfila, Menorca, Spain

    Joan Carulla Torrent

  14. Complejo Hospitalario de Pontevedra, Pontevedra, Spain

    Manuel Constenla Figueiras

  15. Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

    Ma. Dolores Isla Casado

  16. Hospital Universitario Alicante, Alicante, Spain

    Bartomeu Massuti Sureda

  17. Clínica Puerta de Hierro, Madrid, Spain

    Mariano Provencio Pulla

  18. Hospital Marqués de Valdecilla, Santander, Spain

    Jaime Sanz Ortiz

Authors
  1. Vicente Alberola Candel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alfredo Carrato Mena
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eduardo Díaz-Rubio García
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pere Gascón Vilaplana
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Manuel González Barón
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Miguel Martín Jiménez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Emilio Alba Conejo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Javier Cassinello Espinosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ramon Colomer
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Juan Jesús Cruz Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Agustí Barnadas i Molins
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Carlos Camps Herrero
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ana Ma. Casas Fernández de Tejerina
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Joan Carulla Torrent
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Manuel Constenla Figueiras
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Joaquin Gavilá Gregori
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Ma. Dolores Isla Casado
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Bartomeu Massuti Sureda
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Mariano Provencio Pulla
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. César Augusto Rodríguez Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Jaime Sanz Ortiz
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Spanish Society of Medical Oncology (SEOM)

Corresponding author

Correspondence to Vicente Alberola Candel.

Additional information

Supported by an unrestricted educational grant from MSD Oncology

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alberola Candel, V., Carrato Mena, A., Díaz-Rubio García, E. et al. Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients. Clin Transl Oncol 11, 727–736 (2009). https://doi.org/10.1007/s12094-009-0435-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-009-0435-6

Keywords

Search

Navigation